-+ 0.00%
-+ 0.00%
-+ 0.00%

Spero Therapeutics licenses anti-CD40L antibody SP001 from Innovent in deal worth about US$ 1.1 billion

PUBT·07/14/2026 10:04:31
Listen to the news
Spero Therapeutics licenses anti-CD40L antibody SP001 from Innovent in deal worth about US$ 1.1 billion
  • Spero Therapeutics signed an exclusive license with Innovent Biologics for SP001 (IBI355), a Phase 2-ready third-generation anti-CD40L antibody.
  • Spero secured global rights excluding Greater China, covering development, manufacturing, research, and commercialization.
  • Innovent will receive an upfront payment, up to USD 1.1 billion in milestones, and tiered royalties on net sales in Spero’s territories.
  • Spero plans to start a Phase 2 trial in IgG4-related disease in Q2 2027.
  • Innovent plans a China Phase 2 trial in Sjögren’s disease by early 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Spero Therapeutics Inc. published the original content used to generate this news brief on July 14, 2026, and is solely responsible for the information contained therein.